Acute Coronary Syndrome Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology as well as the Acute Coronary Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore Acute Coronary Syndrome Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Coronary Syndrome Market Report
• In December 2025, Novartis Pharmaceuticals conducted a clinical trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.
• In December 2025, Janssen Research & Development LLC initiated a study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
• The total incident cases of ACS in the United States is estimated to be ~1.3 million in 2024. The cases are expected to increase by 2034.
• In EU4 and the UK, the incident cases of ACS were ~515,400 cases in males and ~270,200 cases in females in 2024.
• There were ~46,400 cases of STEMI and ~35,000 cases of NSTEMI in Japan in 2024.
• The leading Acute Coronary Syndrome Companies such as Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra and others.
• Promising Acute Coronary Syndrome Therapies such as LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others.

Strategize your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Coronary Syndrome Overview
Acute Coronary Syndrome (ACS) is a medical emergency that refers to a spectrum of conditions caused by a sudden reduction or complete blockage of blood flow to the heart muscle, most commonly due to rupture of an atherosclerotic plaque and subsequent thrombus formation in the coronary arteries. It includes unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), which differ in severity and extent of myocardial damage.

Acute Coronary Syndrome Epidemiology
• Total Incident Cases of ACS
• Type-specific Incidence of ACS
• Type-specific Incidence of AMI
• Gender-specific Incidence of ACS

Visit for more about Acute Coronary Syndrome Prevalence @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Coronary Syndrome Marketed Drugs
• LODOCO (colchicine): AGEPHA Pharma
Colchicine, an anti-inflammatory alkaloid, has assumed an important role in the management of cardiovascular inflammation after its first medicinal use in ancient Egypt. Primarily used in high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can add to secondary prevention of major adverse cardiovascular events. As the first FDA-approved targeted anti-inflammatory cardiovascular therapy, colchicine currently has a unique role in the management of atherosclerotic cardiovascular disease.

• REPATHA (evolocumab): Amgen
REPATHA is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. In December 2017, the US FDA approved REPATHA to prevent heart attacks, strokes, and coronary revascularizations in adults with established cardiovascular disease. And later in May 2018, the European Commission also approved a new indication in the REPATHA label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke, or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels.

Acute Coronary Syndrome Emerging Drugs
• FDY-5301: Faraday Pharmaceuticals
FDY-5301 is a patented elemental reducing agent containing sodium iodide. It works to catalytically destroy hydrogen peroxide, which is generated as a response to acute injury and contributes to loss of muscle mass and function. Preclinical studies of FDY-5301 have demonstrated its ability to reduce cardiac and skeletal muscle injury. Phase I data have demonstrated no signs of toxicity in healthy subjects. A Phase II trial of FDY-5301 in treating reperfusion injury following STEMI demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage.

• Dutogliptin: Recardio
Dutogliptin (REC-01), developed by Recardio, is a potent and selective DPP4 inhibitor. Dutogliptin is administered via SC injection; the protein belongs to the class of enzyme inhibitors called gliptins or DPP-IV inhibitors. The combination of G-CSF with dutogliptin significantly enhanced survival and reduced infarct size in the preclinical model. Once the diagnosis of AMI is confirmed and percutaneous intervention and stent implantation are completed, the patient receives or can self-administer daily SC injection of dutogliptin for 2 weeks in co-administration with G-CSF for 5 days. Recardio has received FDA and EMA clearance for a global pivotal Phase III clinical trial in acute myocardial infarction. The trial is planned to initiate in 2025 and serve as the basis to apply for market authorization in major global markets.

Acute Coronary Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Coronary Syndrome market or expected to get launched during the study period. The analysis covers Acute Coronary Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Acute Coronary Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

For more information, visit Acute Coronary Syndrome Medication and Companies @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Coronary Syndrome Marketed Drugs
• LODOCO (colchicine): AGEPHA Pharma
• REPATHA (evolocumab): Amgen

Acute Coronary Syndrome Emerging Drugs
• Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche
• Dutogliptin: Recardio

Scope of the Acute Coronary Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Acute Coronary Syndrome Companies- Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others
• Acute Coronary Syndrome Therapies- LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others
• Acute Coronary Syndrome Therapeutic Assessment: Acute Coronary Syndrome current marketed and Acute Coronary Syndrome emerging therapies
• Acute Coronary Syndrome Market Dynamics: Acute Coronary Syndrome market drivers and Acute Coronary Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute Coronary Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Coronary Syndrome Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Acute Coronary Syndrome Treatment Market @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Acute Coronary Syndrome Market Report Introduction
2. Executive Summary for Acute Coronary Syndrome
3. SWOT analysis of Acute Coronary Syndrome
4. Acute Coronary Syndrome Patient Share (%) Overview at a Glance
5. Acute Coronary Syndrome Market Overview at a Glance
6. Acute Coronary Syndrome Disease Background and Overview
7. Acute Coronary Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Coronary Syndrome
9. Acute Coronary Syndrome Current Treatment and Medical Practices
10. Acute Coronary Syndrome Unmet Needs
11. Acute Coronary Syndrome Emerging Therapies
12. Acute Coronary Syndrome Market Outlook
13. Country-Wise Acute Coronary Syndrome Market Analysis (2020-2034)
14. Acute Coronary Syndrome Market Access and Reimbursement of Therapies
15. Acute Coronary Syndrome Market Drivers
16. Acute Coronary Syndrome Market Barriers
17. Acute Coronary Syndrome Appendix
18. Acute Coronary Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.